MK 0249
Alternative Names: MK-0249Latest Information Update: 28 Aug 2012
At a glance
- Originator Merck & Co
- Class Neuropsychotherapeutics
- Mechanism of Action Histamine H3 receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Alzheimer's disease; Attention-deficit hyperactivity disorder; Obesity; Schizophrenia; Sleep apnoea syndrome
Most Recent Events
- 01 Jun 2012 Pharmacodynamics data from a phase I trial in Sleep apnoea syndrome reported by Merck
- 10 Dec 2009 Adverse events data from a clinical trial in healthy subjects presented at the 48th Annual Meeting of the American College of Neuropsychopharmacology (ACNP-2009)
- 12 Dec 2006 Discontinued - Phase-I for Obesity in USA (unspecified route)